Literature DB >> 26417308

Highlights in tumor metabolome research: Choline metabolism influences integrin expression and supports cell attachment.

Ahmed Ghallab1.   

Abstract

Entities:  

Year:  2014        PMID: 26417308      PMCID: PMC4464261     

Source DB:  PubMed          Journal:  EXCLI J        ISSN: 1611-2156            Impact factor:   4.068


× No keyword cloud information.

Dear Editor,

Cell attachment or adhesion, either to another cell or a matrix, is a critical feature of many cell types. For example, immune cells attach to endothelial cells that make up the blood vessels before they enter inflamed tissue. Attachment to the endothelium by circulating tumor cells is also a critical step in metastasis. Therefore, it is of high interest to identify key factors that modify a cell’s ability to attach. In a recent issue of Cell Adhesion and Migration, Lesjak and colleagues demonstrated that choline metabolism strongly influences adhesion of breast and ovarian cancer cells to a fibronectin matrix (Lesjak et al., 2014[9]). In this study, the authors focused on EDI3 (synonym: GDE5 or GPCD1) a key enzyme in choline metabolism that was recently shown to cleave glycerophosphocholine (GPC) in tumor cells (Stewart et al., 2012[20]). One of the cleavage products is choline, the substrate of choline kinase (Marchan et al., 2012[12]). Currently, many studies focus on choline kinase as a potential target for cancer therapy; indeed, expression of this enzyme has been shown to be increased in many carcinomas (Iorio et al., 2005[7], 2010[8]; Gallego-Ortega et al., 2011[4]; Ramírez de Molina et al., 2002[14],[15]). The second cleavage product of EDI3 is glycerol-3-phosphate, which can further be metabolized to lysophosphatidic acid, phosphatidic acid and diacylglycerol (Stewart et al., 2012[20]). A key experiment in the present study of Lesjak et al. (2014[9]) was that silencing EDI3 in breast and ovarian cancer cell lines reduced expression of integrin beta 1. This key integrin receptor can bind to any one of a number of integrin alpha receptors, thus influencing binding to different extracellular matrices, such as fibronectin, laminin and collagen. The binding or heterodimerization of alpha-beta integrins also regulates integrin-mediated signaling, which controls processes such as migration, proliferation, differentiation, attachment and even death (Spangenberg et al., 2006[19]). In addition to reduced integrin beta 1 expression, silencing of EDI3 in these two cancer cell lines resulted in decreased attachment and spreading on a fibronectin matrix. Conversely, overexpressing EDI3 led to enhanced integrin beta 1 expression, increased attachment and spreading. However, a question that still remains open is the mechanism by which EDI3 influences integrin expression. There is currently a great deal of research focused on understanding which mechanisms influence tumor metastasis and prognosis of carcinomas (Schmidt et al., 2008[16]; Cadenas, 2012[10]; Lesjak et al., 2014[9]; Thanopoulou and Judson, 2012[21]; Mamas et al., 2011[10]; Hammad, 2013[6]). Typical factors of influence include adhesion molecules (Micke et al., 2014[13]; Schmidt et al., 2008[16]; 2011[18]; Botling et al., 2013[1]), components of the immune system (Schmidt et al., 2012[17]; Godoy et al., 2014[5]), and redox factors (Cadenas et al., 2010[3]). Although much effort is invested towards elucidating the influence of tumor metabolism on cancer development, the present study of Lesjak et al. (2014[9]) is the first to link choline metabolism to tumor cell attachment. These initial observations set the stage for future studies which will focus on whether choline metabolism can be pharmaceutically modified to reduce the capacity of tumor cells to attach and form metastasis.
  18 in total

Review 1.  Involvement of human choline kinase alpha and beta in carcinogenesis: a different role in lipid metabolism and biological functions.

Authors:  David Gallego-Ortega; Teresa Gómez del Pulgar; Fátima Valdés-Mora; Arancha Cebrián; Juan Carlos Lacal
Journal:  Adv Enzyme Regul       Date:  2010-10-28

2.  Ep-CAM RNA expression predicts metastasis-free survival in three cohorts of untreated node-negative breast cancer.

Authors:  Marcus Schmidt; Ilka Brigitte Petry; Daniel Böhm; Antje Lebrecht; Christian von Törne; Susanne Gebhard; Aslihan Gerhold-Ay; Cristina Cotarelo; Marco Battista; Wiebke Schormann; Evgenia Freis; Silvia Selinski; Katja Ickstadt; Jörg Rahnenführer; Martin Sebastian; Martin Schuler; Heinz Koelbl; Mathias Gehrmann; Jan G Hengstler
Journal:  Breast Cancer Res Treat       Date:  2010-03-30       Impact factor: 4.872

Review 3.  The safety profile of imatinib in CML and GIST: long-term considerations.

Authors:  Eirini Thanopoulou; Ian Judson
Journal:  Arch Toxicol       Date:  2011-06-30       Impact factor: 5.153

4.  Aberrantly activated claudin 6 and 18.2 as potential therapy targets in non-small-cell lung cancer.

Authors:  Patrick Micke; Johanna Sofia Margareta Mattsson; Karolina Edlund; Miriam Lohr; Karin Jirström; Anders Berglund; Johan Botling; Jörg Rahnenfuehrer; Millaray Marincevic; Fredrik Pontén; Simon Ekman; Jan Hengstler; Stefan Wöll; Ugur Sahin; Ozlem Türeci
Journal:  Int J Cancer       Date:  2014-04-08       Impact factor: 7.396

5.  Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers.

Authors:  Ana Ramírez de Molina; Agustín Rodríguez-González; Ruth Gutiérrez; Luis Martínez-Piñeiro; José Sánchez; Félix Bonilla; Rafael Rosell; Juan Lacal
Journal:  Biochem Biophys Res Commun       Date:  2002-08-23       Impact factor: 3.575

6.  Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer.

Authors:  Cristina Cadenas; Dennis Franckenstein; Marcus Schmidt; Mathias Gehrmann; Matthias Hermes; Bettina Geppert; Wiebke Schormann; Lindsey J Maccoux; Markus Schug; Anika Schumann; Christian Wilhelm; Evgenia Freis; Katja Ickstadt; Jörg Rahnenführer; Jörg I Baumbach; Albert Sickmann; Jan G Hengstler
Journal:  Breast Cancer Res       Date:  2010-06-28       Impact factor: 6.466

7.  Interferon-inducible guanylate binding protein (GBP2) is associated with better prognosis in breast cancer and indicates an efficient T cell response.

Authors:  Patricio Godoy; Cristina Cadenas; Birte Hellwig; Rosemarie Marchan; Joanna Stewart; Raymond Reif; Miriam Lohr; Matthias Gehrmann; Jörg Rahnenführer; Markus Schmidt; Jan G Hengstler
Journal:  Breast Cancer       Date:  2012-09-22       Impact factor: 4.239

8.  Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.

Authors:  Ana Ramírez de Molina; Ruth Gutiérrez; Maria Angeles Ramos; José María Silva; Javier Silva; Félix Bonilla; José Javier Sánchez; Juan Carlos Lacal
Journal:  Oncogene       Date:  2002-06-20       Impact factor: 9.867

Review 9.  The role of metabolites and metabolomics in clinically applicable biomarkers of disease.

Authors:  Mamas Mamas; Warwick B Dunn; Ludwig Neyses; Royston Goodacre
Journal:  Arch Toxicol       Date:  2010-10-16       Impact factor: 5.153

10.  EDI3 links choline metabolism to integrin expression, cell adhesion and spreading.

Authors:  Michaela S Lesjak; Rosemarie Marchan; Joanna D Stewart; Eugen Rempel; Jörg Rahnenführer; Jan G Hengstler
Journal:  Cell Adh Migr       Date:  2014-10-31       Impact factor: 3.405

View more
  1 in total

1.  Highlight report: Role of the circadian clock system in breast cancer.

Authors:  Ahmed Ghallab
Journal:  EXCLI J       Date:  2015-04-14       Impact factor: 4.068

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.